|About T.S. Wiley|
A Beverly Hills, California-based medical practitioner, Dr. Christian Renna said that he believes T.S Wiley has made, “one of the most important discoveries in this century” a simple molecular mechanism that up until now, everyone else has missed. Her revolutionary discovery is the fact that it’s the rhythm that matters in the accurate physiological replacement of hormones without side-effects for women in the second half of life. Wiley’s findings may have important implications across a wide range of areas, from the treatment of menopause and anti-aging to all of the other diseases of aging such as heart disease and stroke, Type II diabetes, cancer and Alzheimer’s disease.
The heart of Wiley’s endocrine research in women is based in chronobiology and circadian rhythmicity. Her work rests on the simple fact that the circadian clock in every cell of every human body measures one spin of the earth, and the planet’s constant companion, the moon, tracks 28 days 13 times in one revolution around the sun.
This light and dark cycle response on hormone receptors has evolved the 28 day menstrual cycle embedded in the physiological make-up of all women. That’s why replacing hormones for women with static one-time-a-day, same-amount-every-day, dosing has been so unsuccessfully lethal that most women get sick and some women die whether they take synthetic or bio-identical hormones in such a non-natural regimen.
After years of research, T.S. Wiley created The Wiley Protocol®, a patent protected delivery system consisting of bio-identical estradiol and progesterone in topical cream preparations dosed to mimic the natural hormones produced by a twenty year-old woman. The creams and their amounts vary throughout the 28 day cycle to mimic the hormone levels of youth. The Protocol is the only bio-identical hormone replacement therapy (BHRT) that has ever been developed under the scrutiny of a practicing oncologist.
Fixed VGA fail to show in
T. S. Wiley spent eight years in private tutorial in molecular biology with Dr. Bent Formby, PH. D., and has been in clinical private tutorial in oncology with Dr. Julie Taguchi since 1998. She has also been a guest investigator at Sansum Medical Research Institute, Santa Barbara, CA. Her focus is on what she refers to as Darwinian Medicine or “environmental endocrinology” and evolutionary biology as it pertains to molecular medicine, oncology and genetics.
Professional Affiliations A member of the New York Academy of Sciences, and the American Anthropological Association, Wiley often lectures, and has been a keynote speaker at the following venues:
* International Hormone Society, "Multi-Phasic, Cyclical Hormone Replacement Therapy with Bio-Identical E2/P4" in December 2005
* Keynote speaker, American College for Advancement in Medicine (ACAM), “Multi-Phasic, Cyclical Hormone Therapy with Bio-Identical E2/P4, Clinical Aspects” in May 2005
* Presenter, World Conference on Breast Cancer, “Natural progesterone and the evolution of breast cancer” in Kingston, Ontario, Canada, 1997.
Wiley has made numerous national radio and television appearances and since 2000 continues to present and lecture on Multi-Phasic, Rhythmic Cyclic BHRT and Hibernation and Metabolic States. Wiley’s Seminar’s on the Natural History of Endocrinology are attended by physicians from all over the world and they are awarded CME credits for her work.
Peer Reviewed Journals
* Stern R, Shuster S, Wiley TS, Formby B. Hyaluronidase can modulate expression of CD44. Exp Cell Res. 2001 May 15; 266(1):167-76. * Formby B, Wiley TS. Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol Cell Biochem. 1999 Dec; 202(1-2):53-61.
* Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci. 1998 Nov-Dec; 28(6):360-9.
* Formby B, Wiley TS. Insulin modulates expression of the estrogen-induced genes Bcl-2, c-fos and LucCa-2 in MCF-7 breast tumor cells: evidence for association between breast cancer risk and Type 2 diabetes? Diabetes, poster presentation, American Diabetes Association, June 16, 1997.
* “Protocol for the study of natural progesterone and its clinical effects on advanced metastic cancer.” with Dr. Bent Formby and Dr. Julie Taguchi 1999 (not reported)
* “Randomized, placebo controlled, double blind trial of testosterone in men with elevated age specific PSA and benign prostatic hypertrophy.” with Dr. David Laub and Dr. Julie Taguchi 1999 (as yet unpublished)
* “Natural progesterone for the treatment of multiple forms of cancer.” 1998 (U.S. patent-pending)
* "Insulin for Cosmetic Use" 1999 (U.S. patent)
* "Multi-Phasic, Rhythmic, Cyclic Dosing, The Wiley Protocol" 2004 (U.S. patent protected)
* B.H.O.T. Bio-identical Hormones On Trial: A Comparison of Routes of Administration and Dosing Patterns of Compounded Bio-Identical Hormone Therapy. Study Team: Julie Taguchi, MD, oncologist and clinical researcher, Sansum Clinic, Santa Barbara, California, Janith Williams, DNP, WHNP, RNP, researcher, consultant, clinician and faculty member, Assistant Professor, College of Nursing and Health Sciences, The University of Texas at Tyler. Other teams members include GYN/OB MD's, Functional Medicine MD's, Doctorate of Pharmacy compounding pharmacists, biostatisticians, and 10-12 primary care providers with expertise in care of peri-menopausal and menopausal women. The study has an Advisory Board with nationally recognized content experts and researchers. Study is IRB #Sp2007-27, The University of Texas at Tyler, Tyler , Texas . Study initiated fall 2008.
* "Oral versus Transdermal (cream) Estradiol plus Estriol With Sequential Oral or Transdermal Progesterone, Transdermal Estradiol Patch with Oral Progesterone Versus A Control Arm in Peri-Menopausal Women "(IRB approved pending start date) Projected October 2008